Unique Crypto Strategies
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

Unique Crypto Strategies

Investing

Sona Nanotech’s Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference

by February 12, 2025
February 12, 2025
Sona Nanotech’s Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the ‘Company’, ‘Sona’) is pleased to announce that its recently published findings from its ‘Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically ‘Cold’ Tumors’ study will be presented at the international 19th Canadian Melanoma Conference on February 20th in Vancouver. Sona’s Chief Medical Officer, Dr. Carman Giacomantonio, a planning committee member for this conference, and Dr. Barry Kennedy, of The Giacomantonio Immuno-Oncology Research Group, will present both poster and oral presentations.

The conference is presented by OncologyEducation and is Canada’s flagship meeting on the research and treatment of melanoma, bringing together medical oncologists, surgeons, dermatologists, radiotherapists, pathologists, immunologists, molecular biologists and industry partners to review the latest research and explore new therapies.

Contact:
David Regan, CEO
+1-902-442-0653
david@sonanano.com

About Sona Nanotech Inc.
Sona Nanotech is developing Targeted Hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona’s gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech’s gold nanorod particles are cetyltrimethylammonium (‘CTAB’) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain ‘forward-looking statements’ under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, and Sona’s preclinical and clinical study plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Not for distribution to United States newswire services or for dissemination in the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240541

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Heliostar Metals: Gold Miner with a Portfolio of Producing, Developing Gold Projects in Mexico
next post
Silver47 Identifies Critical Minerals Antimony and Gallium Potential in Addition to the High-Grade Silver-Gold-Zinc at the Red Mountain Project, Alaska

You may also like

Highly successful first milling campaign completed

VRIC 2025: Experts Tout Hard Assets, Energy as...

Deadly Illegal Gold Mine Collapse in Mali Kills...

Key Mining Approval Received for Fountain Head Gold...

Trillion Energy Announces CEO Retirement and New Management...

Top 5 US Oil and Gas Dividend Stocks...

Piedra Redonda Gas Project Assessment Unlocks Multiple Development...

E-Power Starts Metallurgical Testwork at SGS Canada Inc

BTR commences Fish Mine on schedule and under...

Crypto Market Update: Q3 2024 in Review

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • NorthStar Gaming Announces Receipt of Management Cease Trade Order

    • Department of Justice opens criminal investigation into NY AG Letitia James

    • Brunswick Exploration Announces Brokered Private Placement for Gross Proceeds of up to C$2.5 Million, with a Lead Order from a Strategic Investor

    • Drill Contract Awarded for Elizabeth Hill. Technical Visit Completed to Define Drill Targets

    • $2.6M Placement and SPP to fast-track China entry and sales

    Categories

    • Business (439)
    • Investing (2,067)
    • Politics (3,419)
    • Uncategorized (1)
    • World (2,180)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: uniquecryptostrategies.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 uniquecryptostrategies.com | All Rights Reserved


    Back To Top